PHARMACEUTICAL IP

Patent law

Sector insights...

Optogenetics wins the 2026 Nobel Prize in Physiology or Medicine

Congratulations to Professor Karl Deisseroth (The Howard Hughes Medical Institute and Stanford University), Professor Peter Hegemann (Humboldt University of Berlin) and Professor Georg Nagel (University of Würzburg), who were jointly awarded the 2026 Nobel Prize in Physiology or Medicine for their discoveries concerning light-gated ion channels and their pioneering contributions to the field of optogenetics.…

G1/25: What are the consequences?

Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.

Albert – Construe: defining your claims before they are defined for you.

Albert – Construe is the latest addition to Evolve’s proprietary AI toolkit.  It construes a set of claims, sets out with supporting evidence what each unclear term means, highlights any inconsistencies caused by other disclosures within an application, and flags where amendments may have changed the scope of a claim term.

Evolve Intellectual Property ranked in IAM Patent 1000

We are proud to announce that Evolve IP has been ranked in the 2026 publication of the IAM Patent 1000: United Kingdom – England and Wales. This year’s guide highlights our deep technical expertise in life sciences and our practical, strategic business focus. Congratulations to our patent attorneys, Steven Gurney who is ranked Silver and Rose Hughes who is…

IP Stars: Evolve recognised in 2026 Publication

We are delighted to announce that Evolve IP has been recognised in the 2026 IP STARS rankings. This distinction reflects our team’s ongoing dedication to exceptional intellectual property support, featuring key individual accolades for our patent attorneys. Steven Gurney has been recognised as a Patent Star. This specific ranking is awarded to senior practitioners who demonstrate proven excellence in…

Evolve Intellectual Property recognised in Legal500 rankings

Evolve Intellectual property is delighted to once again be recognised in the 2026 edition of Legal 500 for our growing specialised life science IP Practice in Cambridge, UK. The publication highlights Steven Gurney (founder and European, UK, and Australian patent attorney) for his work protecting key biopharmaceutical assets and for his focus on complex prosecution…

G1/25: What are the consequences?

Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.

AI in the patent industry: Beware the MCP Trojan horse

As patent attorneys, we should all know by now not to put client confidential information to a non-enterprise version of an LLM. However, as the capabilities of AI tools become more complex, so too does the necessity of understanding what exactly they are doing and where our data goes, beyond the simple prompt.
View more Insights